ArticlePloS one2020

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Benjamin Birkner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.